Cytomegalovirus in solid organ transplantation

Area of Science:

• Virology
• Immunology
• Transplantation Medicine

Background:

• Cytomegalovirus (CMV) is a significant pathogen in solid organ transplantation (SOT), posing challenges despite treatment advances.
• CMV serves as a model for understanding other human herpesviruses and informs broader viral infection management strategies.
• Expert consensus highlighted the need for comprehensive strategies to address CMV in SOT.

Purpose of the Study:

• To convene experts in SOT to discuss critical issues surrounding CMV infection in transplant recipients.
• To explore the clinical implications, economic impact, and therapeutic options for CMV in SOT.
• To disseminate current knowledge and best practices regarding CMV management in transplant settings.

Main Methods:

• A symposium of experts in solid organ transplantation convened to discuss CMV.
• Presentations and discussions covered various aspects of CMV infection, including drug resistance, economic burden, and therapeutic interventions.
• Additional material was generated based on audience questions, focusing on CMV-IGIV development and resource utilization.

Main Results:

• The symposium addressed the clinical implications of CMV drug resistance and its economic impact on transplant programs.
• The rationale and clinical use of CMV hyperimmune globulin (CMV-IGIV, CytoGam) in SOT were discussed.
• The role of CMV in allograft vasculopathy and hypogammaglobulinemia was examined, alongside resource utilization for CMV-related readmissions.

Conclusions:

• CMV remains a primary concern in SOT, necessitating ongoing research and optimized management strategies.
• CMV-IGIV (CytoGam) is a key therapeutic consideration for CMV management in SOT patients.
• Effective control of CMV in SOT requires addressing drug resistance, economic factors, and specific clinical complications.